Increased Plasma Levels of Nesfatin-1 in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

Abstract

Background:

Nesfatin-1, which is derived from nucleobindin2 (NUCB2), has been recently identified as a novel satiety regulator. However, its pathophysiological role in humans remains unknown. The aim of the present study was to investigate plasma nesfatin-1 levels and the association between plasma nesfatin-1 levels and various metabolic parameters in humans.

Materials and methods:

74 subjects with newly diagnosed type 2 diabetes mellitus (nT2DM), 73 subjects with impaired glucose tolerance (IGT) and 73 subjects with normal glucose tolerance (NGT) were enrolled in this study. Plasma nesfatin-1 levels were measured by a commercially available enzyme- linked immunosorbent assay.

Results:

Plasma nesfatin-1 levels were elevated in subjects with both nT2DM and IGT compared to controls (1.91±0.79 and 1.80±0.80 vs. 1.41±0.58 μ g/L, P<0.05 or P<0.01 ). Simple regression analysis showed that in subjects with IGT and nT2DM, plasma nesfatin-1 correlated positively with body mass index (BMI), hemoglobin A₁c (HbA_1c), fasting blood glucose (FBG), 2 h blood glucose after a glucose load (2hPBG), fasting plasma insulin (FINS) and the homeostasis model assessment of insulin resistance (HOMA-_IR). Multivariate logistic regression analysis revealed that plasma nesfatin-1 was significantly associated with IGT and nT2DM, even after controlling for differences in BMI.

Conclusion:

Plasma nesfatin-1 concentrations were found to be elevated in subjects with both IGT and nT2DM and to be related with several clinical parameters known to be associated with insulin resistance.

Key words

insulin resistance - type 2 diabetes mellitus - nesfatin-1

*

^*  These authors contributed equally to this project.

• References

• 1 Oh-I S, Shimizu H, Satoh T et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006; 443: 709-712
• 2 Johnstone LE, Fong TM, Leng G. Neuronal activation in the hypothalamus and brainstem during feeding in rats. Cell Metab 2006; 4: 257-258
• 3 Stengel A, Goebel M, Wang L et al. Central nesfatin-1 reduces dark-phase food intake and gastric emptying in rats: differential role of corticotropin-releasing factor2 receptor. Endocrinology 2009; 150: 4911-4919
• 4 Shimizu H, Oh-I S, Hashimoto K et al. Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin-independent mechanism. Endocrinology 2009; 150: 662-671
• 5 Kohno D, Nakata M, Maejima Y et al. Nesfatin-1 neurons in paraventricular and supraoptic nuclei of the rat hypothalamus coexpress oxytocin and vasopressin and are activated by refeeding. Endocrinology 2008; 149: 1295-1301
• 6 Stengel A, Goebel M, Yakubov I et al. Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology 2009; 150: 232-238
• 7 Goebel M, Stengel A, Wang L et al. Nesfatin-1 immunoreactivity in rat brain and spinal cord autonomic nuclei. Neurosci Lett 2009; 452: 241-246
• 8 Foo KS, Brauner H, Ostenson CG et al. Nucleobindin-2/nesfatin in the endocrine pancreas: distribution and relationship to glycaemic state. J Endocrinol 2010; 204: 255-263
• 9 Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Enodocrinol Metab 2008; 93: S64-S73
• 10 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabetic Med 1998; 15: 539-553
• 11 Albareda M, Rodriguez-Espinosi J, Murugo M et al. Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. Diabetologia 2000; 43: 1507-1511
• 12 Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifugation. Clin Chem 1972; 8: 499-502
• 13 Ramanjaneya M, Chen J, Brown JE et al. Identification of nesfatin-1 in human and murine adipose tissue: A novel depot-specific adipokine with increased levels in obesity. Endocrinology 2010; 151: 1358-1363
• 14 Taylor SI, Accili D, Imai Y. Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM?. Diabetes 1994; 43: 735-740
• 15 Li QC, Wang HY, Chen X et al. Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul Pept 2010; 159: 72-77
• 16 Gonzalez R, Tiwari A, Unniappan S. Pancreatic beta cells colocalize insulin and pronesfatin immunoreactivity in rodents. Bio Bio Res Commun 2009; 381: 643-648
• 17 Tan BK, Hallschmid M, Kern W et al. Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/nucb-2, in obese human: evidence of nesfatin-1/nucb-2 resistance and implications for obesity treatment. JCEM 2011; 96: E669-E673
• 18 Ogiso K, Asakawa A, Amitani H et al. Plasma nesfatin-1 concentration in restricting-type anorexia nervosa. Peptide 2011; 32: 150-153
• 19 Aydin S, Dag E, Ozkan Y et al. Nesfatin-1and ghrelin levels in serum and saliva of epileptic patients: hormonal changes can have a major effect on seizure disorders. Mol Cell Biochem 2009; 328: 49-56